Relapse Prevention and the Need for Ongoing Pharmacological Treatment in Body Dysmorphic Disorder.

An editorial is presented on a study conducted by the researcher K.A. Phillips on prevention of deterioration after disease and requirement of pharmaceutical research on body dysmorphic disorder (BDD). Topics discussed include classification of BDD as an obsessive-compulsive disorder (OCD) and related disorder, presentation of selective efficacy of treatment response to serotonin reuptake inhibitors (SRIs) and study of pharmacotherapy continuation and discontinuation in patients with (BDD).